Trial Profile
A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Rituximab (Primary) ; Sirolimus (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 27 Nov 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov .(NCT01116232).
- 27 Nov 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov .(NCT01116232).
- 30 Jul 2012 Planned end date changed from 1 Jun 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov (NCT01534767).